- Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
- Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
- Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
- Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
- Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
More ▼
Key statistics
As of last trade, Gyre Therapeutics Inc (GYRE:NAQ) traded at 12.32, 156.56% above the 52 week low of 4.80 set on Oct 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.44 |
---|---|
High | 12.80 |
Low | 12.30 |
Bid | 12.20 |
Offer | 12.43 |
Previous close | 12.43 |
Average volume | 188.23k |
---|---|
Shares outstanding | 85.51m |
Free float | 15.62m |
P/E (TTM) | -- |
Market cap | 1.06bn USD |
EPS (TTM) | -1.88 USD |
Data delayed at least 15 minutes, as of Jul 08 2024 16:01 BST.
More ▼